By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Principia Biopharma 

400 East Jamie Court
Suite 302
South San Francisco   California  94080  U.S.A.
Phone: 650-416-7700 Fax:


Company News
Principia Biopharma Announces PRN1008 Receives Orphan Drug Designation From FDA For Treatment Of Pemphigus Vulgaris 7/11/2017 8:13:43 AM
AbbVie (ABBV) And Principia Biopharma Announce Collaboration On Oral Immunoproteasome Inhibitors 6/13/2017 7:48:08 AM
ASCO2016: Principia Biopharma Announces Presentation Of Initial Clinical Data On PRN1371 At 2016 American Society Of Clinical Oncology (ASCO) Annual Meeting 6/6/2016 8:17:48 AM
Guardant Health Announces Collaboration With Principia Biopharma To Use Guardant360 For Monitoring Patient Response And Tumor Evolution In FGFR Inhibitor Trials 3/29/2016 7:41:32 AM
Principia Biopharma Advances BTK Inhibitor Program In Autoimmune Disease And FGFR Inhibitor Program In Oncology 1/7/2016 11:19:38 AM
Principia Biopharma Presents Full Phase 1 Clinical Trial Results For PRN1008, A Novel Reversible Covalent BTK Inhibitor, Supporting Further Clinical Development In Autoimmune And Inflammatory Diseases 6/15/2015 10:58:54 AM
Principia Biopharma And University of California, San Francisco (UCSF) Scientists Announce Publication Of Seminal Paper On Reversible Covalent Drugs In Nature Chemical Biology 5/26/2015 8:30:18 AM
Principia Biopharma Appoints Roy Hardiman As Chief Business Officer And Lewis Shuster To Board Of Directors 1/12/2015 10:27:43 AM
Principia Biopharma Successfully Completes Phase 1 Clinical Trial Of PRN1008, A Novel Oral BTK Inhibitor For Autoimmune Diseases 1/8/2015 11:25:56 AM
Bay Area's Principia Biopharma Secures $50 Million Series B Financing 4/22/2014 6:48:57 AM